ClinicalTrials.gg
Not yet recruitingNCT07617194EXTEND-101Updated Jun 1, 2026

Study of AHB-171 in Chronic Hepatitis B Participants

A Phase 1 interventional study of AHB-171 and Placebo matching [Investigational Product] in Hepatitis B, Chronic, sponsored by AusperBio Therapeutics Inc.. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by AusperBio Therapeutics Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Hepatitis B, Chronic with a site in Hong Kong — 9 open to participants now, 15 under way, none of them phase 3. Hepatitis B, Chronic · Hong Kong.

Planned enrollment
30th of 79
144 · median 114
Started
2026
with 1 other
Phase 1
22 of 88
4 open now
Primary completion
2027-10
later than 9 of 14 live
Registered
88th of 88
by date
Lead sponsor
2 of 88
AusperBio Therapeutics Inc.

Among the 88 studies in Hepatitis B, Chronic with a site in Hong Kong, this one is the 30th largest by planned enrollment of the 79 interventional ones that give a count, is one of 2 that started in 2026, is one of 22 in phase 1, reaches primary completion later than 9 of the 14 other live ones, and was the 88th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

9 of the 88 studies in Hepatitis B, Chronic with a site in Hong Kong are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Hepatitis B, Chronic with a site in Hong Kong, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB). Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants, aged 18-65 years old (inclusive)
  • between 19 to 35 kg/m2 (inclusive)
  • Body weight > or = 45 kg.
  • Documented infection for ≥6 months prior to randomization.
  • For Parts A and B, on stable approved NA monotherapy for at least 6 months prior to randomization.
  • For Part C and D only, not on any NA monotherapy for at least 6 months prior to randomization.
  • Screening (ECG) without abnormalities
  • Females of must not be breastfeeding, must have a negative serum pregnancy test at Screening, and a negative urine/serum pregnancy test before dosing (unless permanently sterile or >2 years ).
  • Males and females of childbearing potential must agree to use protocol specified reliable throughout the study.
  • Screening HBV DNA, HBsAg and must meet prespecified requirements.

Exclusion criteria

Exclusion Criteria:

  • Significant medical conditions other than chronic (e.g. recent heart issues, unstable cardiac disease, uncontrolled diabetes, bleeding disorders, prior organ transplant).
  • Other liver diseases (e.g. hepatitis from other causes, or alcoholic liver disease, prior liver failure).
  • History of suspected or confirmed cirrhosis (based on FibroScan® or ).
  • Current, past, or suspected liver cancer, or elevated alpha-fetoprotein (AFP) ≥ 20 ng/mL.
  • HBV-related extrahepatic diseases (e.g. kidney or vascular conditions).
  • Severe infection (other than chronic HBV infection) within 1 month before randomization requiring intravenous treatment.
  • Active infections: (HIV), virus (HCV), hepatitis D virus (HDV) or syphilis (exceptions if RNA negative).
  • Abnormal lab results (e.g. low albumin, reduced kidney function, abnormal , low , high , abnormal blood counts, significant proteinuria).
  • History or signs of vasculitis or related autoimmune diseases.
  • within 5 years (except non-melanoma skin cancer).
  • Allergy to study drug components.
  • Recent major surgery/trauma (within 3 months) or planned surgery during study.
  • Alcohol or substance abuse affecting compliance.
  • Pregnancy, breastfeeding, or unwillingness to follow reproductive restrictions.
  • Participation in another clinical trial or recent product use.
  • Prior treatment with any antisense oligonucleotide or small interfering RNA therapies.
  • Recent or ongoing use of /biologic therapies, certain vaccines, bulevirtide, or unapproved herbal remedies.
  • Need for long-term anticoagulants/antiplatelet drugs (unless safely stopped).
  • Any other condition making the participant unsuitable (per investigator).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    AHB-171 or Placebo in CHB (Part A: Single Ascending Dose [SAD])

    Drug: AHB-171 · Drug: Placebo matching [Investigational Product] · Drug: Nucleos(t)ide Analogue (NA)

  • Experimental
    AHB-171 or Placebo in CHB (Part B: finite Multiple Dose [MD])

    Drug: AHB-171 · Drug: Placebo matching [Investigational Product] · Drug: Nucleos(t)ide Analogue (NA)

  • Experimental
    AHB-171 and placebo in CHB (Part C: finite MD)

    Drug: AHB-171 · Drug: Placebo matching [Investigational Product]

  • Experimental
    AHB-171 and placebo in CHB (Part D: finite MD)

    Drug: AHB-171 · Drug: Placebo matching [Investigational Product]

Interventions

  • Injection

  • DrugPlacebo matching [Investigational Product]

    Injection

  • DrugNucleos(t)ide Analogue (NA)

    Oral administration

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) [Safety and Tolerability]

    Time frame: Up to 72 weeks

  2. The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: the maximum observed plasma concentration (Cmax) of AHB-171.

    Time frame: Up to 72 weeks

  3. The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: the area under the concentration-time curve extrapolated to infinity (AUCinf ) of AHB-171

    Time frame: Up to 72 weeks

  4. Incidence of clinically significant changes in Vital Signs [Safety and Tolerability]

    Vital signs include body temperature, pulse rate, respiratory rate, and blood pressure

    Time frame: Up to 72 weeks

  5. Incidence of clinically significant changes in cardiac parameters [Safety and Tolerability]

    12-lead electrocardiogram (ECG) abnormalities will be reported, with parameters evaluated including PR interval, QRS duration, QT/QTc interval.

    Time frame: Up to 72 weeks

  6. Incidence of laboratory abnormalities [Safety and Tolerability]

    Time frame: Up to 72 weeks

  7. The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: area under the curve from the time of dosing to the last measurable concentration (AUClast) of AHB-171

    Time frame: Up to 72 weeks

Secondary outcomes

  1. Absolute serum HBsAg (Hepatitis B surface antigen) and change from baseline across all evaluated timepoints in the study

    Time frame: Up to 72 weeks

  2. Absolute serum HBV (Hepatitis B virus) DNA and change from baseline across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  3. Absolute serum HBeAb (Hepatitis B e Antibody) and change from baseline across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  4. Proportion of participants achieving pre-specified HBsAg reduction levels or absolute thresholds across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  5. Proportion of participants achieving HBsAg < or ≥ LOD (limit of detection) and/or HBV DNA < or ≥ LLOQ (lower limit of quantitation) across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  6. Proportion of participants achieving pre-specified HBV DNA levels or absolute thresholds across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  7. Time to achieving pre-specified HBsAg levels or absolute thresholds across all evaluated timepoints in the study

    Time frame: Up to 72 weeks

  8. Change from baseline in alanine aminotransferase (ALT) levels

    Time frame: Up to 72 weeks

  9. Proportion of participants with ALT normalization among those with elevated ALT at baseline across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  10. Proportion of participants achieving anti-HBs seroconversion across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  11. Proportion of participants experiencing virologic relapse.

    Virologic relapse is defined as HBV DNA meeting a protocol-specified threshold value at 2 consecutive visits

    Time frame: Up to 72 weeks

  12. Time to participants experiencing virologic relapse.

    Virologic relapse is defined as HBV DNA meeting a protocol-specified threshold value at 2 consecutive visits

    Time frame: Up to 72 weeks

  13. Proportion of participants with treatment emergent AEs (TEAEs), serious AEs (SAEs), or discontinuation due to AEs.

    Time frame: Up to 72 weeks

  14. Proportion of participants with anti-drug antibodies (ADA) to AHB-171.

    Time frame: Up to 72 weeks

  15. ADA titers in participants with ADA to AHB-171 across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  16. Plasma PK parameters AUC of AHB-171 and metabolites.

    Time frame: Up to 72 weeks

  17. Plasma PK parameter Cmax of AHB-171 and metabolites.

    Time frame: Up to 72 weeks

  18. Plasma PK parameter Time to Peak Concentration (tmax) of AHB-171 and metabolites.

    Time frame: Up to 72 weeks

  19. Plasma PK parameter apparent clearance (CL [clearance]/F [Bioavailability]) of AHB-171 and metabolites.

    Time frame: Up to 72 weeks

  20. Urine PK parameter cumulative amount excreted (Ae) of AHB-171 and metabolites.

    Time frame: Up to 72 weeks

  21. Urine PK parameter renal clearance (CLr) of AHB-171 and metabolites.

    Time frame: Up to 72 weeks

  22. Absolute serum HBV ribonucleic acid (RNA) and change from baseline across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  23. Absolute serum HBcrAg (Hepatitis B core-related antigen) and change from baseline across all evaluated timepoints in the study

    Time frame: Up to 72 weeks

  24. Absolute serum HBeAg (Hepatitis B e antigen) and change from baseline across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  25. Proportion of participants with hs-HBsAg (high-sensitivity HBsAg) <LLOQ across all evaluated timepoints in the study.

    Time frame: Up to 72 weeks

  26. Absolute serum HBsAb (Hepatitis B surface Antibody) and change from baseline across all evaluated timepoints in the study.

    Time frame: Time Frame: Up to 72 weeks

  27. Time to first hs-HBsAg <LLOQ, assessed at scheduled visits

    Time frame: Up to 72 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2027, 15 months later.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 15 months is close to that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
Jun 1, 2026
StartEst.
Jul 6, 2026
Primary completionEst.
Oct 8, 2027
CompletionEst.
Aug 14, 2028
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07617194
Lead sponsor
AusperBio Therapeutics Inc.
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jul 6, 2026 (estimated)
Primary completion
Oct 8, 2027 (estimated)
Completion
Aug 14, 2028 (estimated)
Last update
Jun 1, 2026

Study contacts

Debbie Liao
Contact
ausperbioclinicaltrials@ausperbio.com
(650) 650-2877

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AHB-171

Start the discussion